Cerus Corp stock (US1570851014): Recent 2.21% gain amid mixed signals
Published on 05/14/2026 at 13:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cerus Corp stock climbed 2.21% on the last trading day, Friday, July 25, 2025, moving from $1.36 to $1.39 on Nasdaq, according to StockInvest.us as of July 28, 2025. The gain comes amid buy signals from short- and long-term moving averages, though the overall evaluation remains negative with a sell candidate score of -1.627.
As of: 14.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Cerus Corporation
- Sector/industry: Medical Devices
- Headquarters/country: United States
- Core markets: Blood safety systems
- Home exchange/listing venue: Nasdaq (CERS)
- Trading currency: USD
Official source
For first-hand information on Cerus Corp, visit the company’s official website.
Go to the official websiteCerus Corp: core business model
Cerus Corporation develops and markets the INTERCEPT Blood System to enhance blood safety by inactivating pathogens in platelets and plasma. The technology targets hospitals, blood banks, and plasma fractionators globally, with a focus on preventing transfusion-transmitted infections. US investors track Cerus for its role in the medical device sector amid rising demand for blood safety solutions.
Main revenue and product drivers for Cerus Corp
Key revenue stems from sales of disposable kits for the INTERCEPT System, used in platelet and plasma processing. In recent periods, the company has expanded into emerging markets, supporting growth. The stock's listing on Nasdaq provides US retail investors direct access to these developments in blood component pathogen inactivation.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Industry trends and competitive position
The medical devices industry sees growth in blood safety technologies, driven by global transfusion needs and pathogen risks. Cerus Corp holds a niche in pathogen reduction systems, competing with limited direct rivals. For US investors, exposure comes via Nasdaq trading and potential FDA-related advancements.
Conclusion
Cerus Corp stock showed a 2.21% increase to $1.39 on July 25, 2025, amid mixed technical signals including buy indications from moving averages but an overall sell rating. The company continues focusing on its INTERCEPT Blood System for blood safety. Investors monitor volume support at $1.34 and resistance levels ahead.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
